INSIGHTS ON CONTRACT PHARMA MANUFACTURING

• Patient-Centric Oral Solid Dose Formulation: Improving Access And Value Across The Product Lifecycle

  This whitepaper provides insight into the systematic application of patient centricity to the design of OSD products.

• mRNA Vaccine Development: Key Insights For Planning, Workflow, And Supply Chain Success

  In this report, we will review key insights derived from the development of mRNA-based COVID-19 vaccines and how they can be applied to accelerate progress in the manufacture of mRNA vaccines and therapeutics moving forward.

• Continuous Manufacturing And Late-Phase Strategy: The Time Is Now

  This report discusses recent progress in continuous manufacturing and provides guidance for answering three key questions related to the implementation of continuous processing for late-phase development of small molecule oral solid dosage forms.

• The Changing Landscape Of Oncology Drug Development: Bringing Novel Lifesaving Therapies To Patients

  This whitepaper provides strategic guidance for successfully navigating such complexities, focusing specifically on: unique formulation and handling requirements, novel trial designs and the supply chain implications, and regulatory and clinical strategies to support product approvals.

• Leveraging Innovations In Plasmid Manufacturing To Bring Advanced Therapies To Market

  This whitepaper provides insight into the market trends influencing the manufacture and supply of pDNA for advanced therapies and offers an in-depth discussion of the key challenges associated with transitioning from GMPlike to full cGMP quality. Guidance is also offered to address these challenges, including recommendations related to critical quality attributes, upstream processing, formulation and fill/finish, analytics, and flexible capacity planning.

• Prepping For Commercialization Through Supply Chain Logistics

  Cell and gene therapies (CGT) are bringing new hope to patients experiencing rare and serious diseases. And they are disrupting the biopharma market in new and challenging ways.

• Going From DNA To IND In 11 Months*

  Lonza’s Ibex®️ Design workflow relies on cutting-edge process platforms, ensuring straightforward scale-up to cGMP manufacturing, as well as new, innovative technologies and workflows that further reduce development time and improve overall productivity.

• Current And New Technologies To Characterize Advanced Therapies: Making The Right Decisions Upstream To Ensure Downstream Success

  Explore the latest strategies and technologies to develop a comprehensive, optimal approach to assay development and product characterization.

• Artful Taste Masking Improves Patient Compliance

  Taste masking is required for dosage forms that interact with the taste buds. Discover some of the best and most practical taste masking methods to consider for each API.

• Oral Solutions & Suspensions: The Art Of Pharmacy

  Despite advantages, there are challenges associated with liquid dosage, such as stability and palatability, parameters that need to be considered in the design.